Colchicine Trial in Adults With Moderate Chronic Kidney Disease

Trial details

Who runs it

Hospital General Universitario Gregorio Marañon

Trial code

NCT06998862EU 2023-505868-11-00

Record updated

31 May 2025

Original description

The ColchiRen study is a phase 3, controlled, prospective, randomized, double-blind, and multicenter clinical trial. Its main objective is to demonstrate the benefit of low-dose colchicine treatment in secondary prevention of cardiovascular events in patients with moderate CKD. As a secondary objective, it aims to explore the potential beneficial anti-inflammatory effect on the progression of CKD.Read full original descriptionShow less

Efficacy of Colchicine in Secondary Prevention of Vascular Events and Renal Progression in Patients With Moderate Chronic Kidney Disease

The ColchiRen study is a phase 3, controlled, prospective, randomized, double-blind, and multicenter clinical trial. Its main objective is to demonstrate the benefit of low-dose colchicine treatment in secondary prevention of cardiovascular events in patients with moderate CKD. As a secondary objective, it aims to explore the potential beneficial anti-inflammatory effect on the progression of CKD.

Inclusion: Age between 18 and 99 years. Moderate chronic kidney disease, defined as an estimated glomerular filtration rate (eGFR) by the CKD-EPI formula between 30 and 59 mL/min/1.73 m²; History of a previous cardiovascular event:; Acute coronary syndrome. Admission for angina pectoris. Transient ischemic attack or non-cardioembolic ischemic stroke. Coronary revascularization. Peripheral vasculopathy, defined as: embolism or acute peripheral arterial ischemia, or the need for amputation or surgical revascularization; Finding of coronary artery disease on imaging test.

Exclusion: Current treatment with colchicine, or within the month prior to inclusion; Hospital admission for any cause within the 3 months prior to study inclusion; Immunosuppressive treatment within the 12 weeks prior to study inclusion; Chronic treatment with non-steroidal anti-inflammatory drugs (NSAIDs); Pregnancy and breastfeeding at the time of inclusion. Contraceptive methods are required for women of reproductive age. Women with no capacity for pregnancy are considered to be those with:; History of hysterectomy, bilateral salpingectomy, bilateral oophorectomy, or bilateral tubal ligation; Documented infertility. Postmenopausal women, defined as amenorrhea for more than 12 months without other medical cause. In case of doubt, confirmation with elevated follicle-stimulating hormone (FSH) levels is recommended; Women of reproductive capacity must use a method of contraception with proven effectiveness until 8 weeks after the end of the study. Acceptable methods include:; Intrauterine device (IUD) placement at least 6 weeks before study inclusion. Hormonal contraception with progestogens only, associated with ovulation inhibition: oral, injectable, or implantable, at least 6 weeks before study inclusion; Progestin-releasing intrauterine system (IUS) at least 6 weeks before study inclusion; Combined hormonal contraception (containing estrogen and progestogens) associated with ovulation inhibition: oral, intravaginal, transdermal, at least 6 weeks before study inclusion; Other contraceptive methods (sexual abstinence, barrier methods, spermicides, etc.) are not considered acceptable for participation in this study; thrombocytopenia <50,000 cells/μL during the month prior to inclusion; Neutropenia defined as <1500 cells/mcL during the month prior to inclusion; Treatment with CYP3A4 inhibitors and/or P-glycoprotein inhibitors (antivirals, azole antifungals, aminoglycosides, cyclosporine) in the month prior to their inclusion in the study; Active malignant neoplasm (except non-melanoma skin cancer or carcinoma in situ). Patients with a history of malignant neoplasm who have remained disease-free for the past 3 years may be included; Uncontrolled or symptomatic chronic inflammatory disease (rheumatoid arthritis, systemic lupus erythematosus, Crohn's disease, ulcerative colitis, etc.); Active infection with hepatitis B virus, hepatitis C virus, or human immunodeficiency virus; Poorly controlled hypertension (>160/90 mmHg) at the time of inclusion; Gastric ulcer; History of aplastic anemia diagnosed through bone marrow biopsy; History of allergy or intolerance to colchicine or any of its excipients (dihydrate calcium hydrogen phosphate, microcrystalline cellulose, anhydrous colloidal silica, magnesium stearate); Anemia defined as hemoglobin <10.5 g/dL during the month prior to inclusion; Liver cirrhosis of any cause, grade B or C according to Child-Pugh.

ClinicalTrials.gov NCT06998862 · EU CTIS 2023-505868-11-00